<DOC>
	<DOCNO>NCT00187109</DOCNO>
	<brief_summary>Life-threatening thrombocytopenia ( low platelet count ) neutropenia ( low white blood count ) remain major dose-limiting toxicity follow chemotherapy treatment cancer . The remedy thrombocytopenia present platelet transfusion , effective prevent life-threatening hemorrhage , may lead complication . Preclinical study study adults show recombinant human thrombopoietin ( rhTPO ) effective stimulating platelet production . The initial phase trial evaluate safety rhTPO use immediately chemotherapy ifosfamide , carboplatin , etoposide child solid tumor lymphomas . The second phase study evaluate effectiveness rhTPO decrease duration low platelet count chemotherapy .</brief_summary>
	<brief_title>Recombinant Human Thrombopoietin Children Receiving Ifosfamide , Carboplatin , Etoposide Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Diagnosis recurrent , refractory , previously untreated malignant solid tumor recurrent/refractory lymphoma Ifosfamide , Carboplatin , Etoposide chemotherapy appropriate treatment . Adequate liver kidney function . Adequate performance status .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Platelets</keyword>
	<keyword>Thrombopoietin</keyword>
</DOC>